Immune Pharmaceuticals Inc (fka IMNPQ)

[Investor100]

Immune Pharmaceuticals Inc

Given the fact the CEO has paid higher prices and this target number of $3.50...buying the dips again!

http://openinsider.com/search?q=imnp

http://www.smarteranalyst.com/2016/06/03/biotech-beat-fbr-analysts-weigh-galena-biopharma-inc-gale-peregrine-pharmaceuticals-pphm-immune-pharmaceuticals-inc-imnp/

Analyst Vernon Bernardino was out pounding the table on Immune Pharmaceuticals Inc (NASDAQ:IMNP), reiterating an Outperform rating and price target of $3.00, which implies an upside of 747.5% from current levels.

Bernardino wrote, “We think IMNP is currently undervalued when considering the collective value of its clinical-stage assets. Following Jazz Pharmaceuticals’ (JAZZ) recent announcement of its $1.5B acquisition of Celator Pharmaceuticals (CPXX) for Vyxeos, the latter’s Phase III stage product candidate for acute myeloid leukemia (AML), we particularly think Ceplene, an IMNP asset already approved in the EU and Israel as a treatment for maintenance of complete response (CR) in patients with AML, alone is undervalued.”

“We believe that Ceplene’s value has been overlooked, and we regard finalizing the design of a U.S. pivotal trial with the FDA as a catalyst that could be positive for IMNP stock later this year,” the analyst added

As of this writing, all the 3 analysts polled by TipRanks rate Immune Pharmaceuticals stock a Buy. With a return potential of 889%, the stock’s consensus target price stands at $3.50.

Investor 100